tetano
Editor, Senior Moderator
Front Pharmacol
. 2022 Apr 6;13:849545.
doi: 10.3389/fphar.2022.849545. eCollection 2022.
Evaluation of the Clinical Effectiveness of Oseltamivir for Influenza Treatment in Children
Jianru Qin[SUP] 1 [/SUP], Jilei Lin[SUP] 2 [/SUP], Xiangfei Zhang[SUP] 1 [/SUP], Shuhua Yuan[SUP] 2 [/SUP], Chiyu Zhang[SUP] 3 [/SUP], Yong Yin[SUP] 2 [/SUP]
Affiliations
Abstract
Objective: To estimate the clinical effectiveness of oseltamivir in children with different subtypes of influenza virus infection. Methods: A total of 998 children with acute respiratory infection were enrolled from January to March 2018, and were divided into influenza A, influenza B, influenza A + B, and non-influenza infection (IV-negative) groups. Influenza-like symptoms and duration of fever were evaluated and compared between oseltamivir-treated and non-treated groups. Results: There were no significant differences in the reduction in total febrile period and duration of fever from the onset of therapy between the oseltamivir treated and non-treated children infected with influenza A (p = 0.6885 for total febrile period and 0.7904 for the duration of fever from the onset of treatment), influenza B (p = 0.1462 and 0.1966), influenza A + B (p = 0.5568 and 0.9320), and IV-negative (p = 0.7631 and 0.4655). The duration of fever in children received oseltamivir therapy within 48 h was not significantly shorter than that beyond 48 h (p > 0.05). Additionally, percentages and severities of influenza-like symptoms, including headache, myalgia, fatigue, bellyache, vomiting, diarrhea, sore throat, cough, and coryza were not decreased and alleviated after treatment of oseltamivir. Conclusion: Oseltamivir treatment does not significantly shorten the duration of fever, nor does it significantly relieve influenza-like symptoms in children with infection of influenza.
Keywords: Oseltamivir; children; clinical effectiveness; influenza; treatment.
. 2022 Apr 6;13:849545.
doi: 10.3389/fphar.2022.849545. eCollection 2022.
Evaluation of the Clinical Effectiveness of Oseltamivir for Influenza Treatment in Children
Jianru Qin[SUP] 1 [/SUP], Jilei Lin[SUP] 2 [/SUP], Xiangfei Zhang[SUP] 1 [/SUP], Shuhua Yuan[SUP] 2 [/SUP], Chiyu Zhang[SUP] 3 [/SUP], Yong Yin[SUP] 2 [/SUP]
Affiliations
- PMID: 35462914
- PMCID: PMC9020783
- DOI: 10.3389/fphar.2022.849545
Abstract
Objective: To estimate the clinical effectiveness of oseltamivir in children with different subtypes of influenza virus infection. Methods: A total of 998 children with acute respiratory infection were enrolled from January to March 2018, and were divided into influenza A, influenza B, influenza A + B, and non-influenza infection (IV-negative) groups. Influenza-like symptoms and duration of fever were evaluated and compared between oseltamivir-treated and non-treated groups. Results: There were no significant differences in the reduction in total febrile period and duration of fever from the onset of therapy between the oseltamivir treated and non-treated children infected with influenza A (p = 0.6885 for total febrile period and 0.7904 for the duration of fever from the onset of treatment), influenza B (p = 0.1462 and 0.1966), influenza A + B (p = 0.5568 and 0.9320), and IV-negative (p = 0.7631 and 0.4655). The duration of fever in children received oseltamivir therapy within 48 h was not significantly shorter than that beyond 48 h (p > 0.05). Additionally, percentages and severities of influenza-like symptoms, including headache, myalgia, fatigue, bellyache, vomiting, diarrhea, sore throat, cough, and coryza were not decreased and alleviated after treatment of oseltamivir. Conclusion: Oseltamivir treatment does not significantly shorten the duration of fever, nor does it significantly relieve influenza-like symptoms in children with infection of influenza.
Keywords: Oseltamivir; children; clinical effectiveness; influenza; treatment.